INTRODUCTION
============

Type-1 diabetes mellitus is characterized by destroyed pancreatic β cells, insulin deficiency and hyperglycemia ([@b1-cln_68p123],[@b2-cln_68p123]). The progression of this process is heterogeneous and may range from months to many years ([@b3-cln_68p123],[@b4-cln_68p123]). For long periods after being diagnosed, some Type-1 diabetes patients maintain a residual β-cell function ([@b5-cln_68p123]) which may be associated with reducing the risk of complications and hypoglycemia and improving metabolic control ([@b6-cln_68p123]-[@b10-cln_68p123]). C-peptide is considered a reliable method for estimating the β-cell residual function ([@b5-cln_68p123]-[@b7-cln_68p123]) particularly after glucagon stimulation or a mixed meal. Most studies that have evaluated the C-peptide secretion in Type-1 diabetes have included Caucasians or Asians. Little is known about insulin secretion in individuals of other ethnicities with Type-1 diabetes. The aim of this study was to evaluate the β-cell function in multiethnic Type-1 diabetes patients with variable disease durations using C-peptide measurements after glucagon stimulation.

RESEARCH DESIGN AND METHODS
===========================

Volunteers who had Type-1 diabetes ([@b11-cln_68p123]) with short (Group 1) and long (Group 2) disease durations (≤5 years and \>5 years, respectively) were included in this cross-sectional study. A diabetes diagnosis was based on the American Diabetes Association criteria ([@b11-cln_68p123]). The patients\' clinical and epidemiological data were obtained from questionnaires and medical records, and all participants provided informed written consent. Blood samples from each patient were measured for fasting glucose and stimulated C-peptide (6 minutes after intravenous injections of 1 mg of glucagon), glycosylated hemoglobin (HbA1C) and anti-glutamic acid decarboxylase antibody (GADA). The tests were performed if a patient\'s fasting capillary glucose measured between 70 and 200 mg/dL. The participants were classified as whites and non-whites based on their phenotypes and family backgrounds. C-peptide was determined using chemiluminescence (Immulite DPC; UK). A C-peptide level ≥0.5 ng/dL was considered detectable (reference 1.1 to 5.0 ng/mL). The inter- and intra-assay coefficients of variation (CV) were 7.6% and 8.2%, respectively. GADA was determined using radioimmunoassay (*RSR-Limited*, Cardiff, UK). Values \>1.0 U/mL were considered positive. The inter- and intra-assay CVs were 4.9 to 7.0% and 3.6 to 3.7%, respectively. The statistical analyses were performed using SAS 6.1 version (SAS Institute Inc., Cary, NC). Chi-squared and Mann Whitney U-tests were used to compare the variables between the groups (all two-tailed, α = 0.05). Spearmańs correlation coefficient was used to test the association between the continuous variables. Logistic regression was used for the multivariate analysis.

RESULTS
=======

The study population comprised 88 individuals with Type-1 diabetes. The characteristics of the study group are shown in [Table 1](#t1-cln_68p123){ref-type="table"}. Fasting C-peptide was detectable in 19 patients (21.6%), and these C-peptide levels were within the normal range in 7 (8%) patients. After the glucagon stimulus, C-peptide was detectable in 31.8% of the patients (n = 28, *p* = 0.004) and within the normal range in 14.8% of the patients (n = 13, *p* = 0.016). The mean C-peptide titers in the patients with detectable C-peptide levels were 1.3±0.8 ng/ml (fasting) and 1.6±1.2 ng/ml (after the stimulus). Given the superiority of C-peptide (after the stimulus) over the fasting measurement, the former was used for the following tests. Adverse events occurred in 35.2% of the patients (n = 30) after the glucagon infusion (e.g., transient mild nausea that was reversible within minutes in most cases, vomiting, paresthesia and malaise).

There was an association between the detectable C-peptide levels and the diabetes disease duration (detectable CP = 5±7.5 vs. undetectable CP = 10±6.99 years, *p*\<0.001), but there was no correlation between the C-peptide titers and the Type-1 diabetes duration (r = -0.342, *p* = 0.08). In group 1, the patients with detectable C-peptide levels had a shorter Type-1 diabetes duration (2.01±1.4 vs. 3.04±1.5 years, *p* = 0.034). The patient\'s age at disease onset, ethnicity, gender, DKA at diagnosis and GADA status were not associated with the C-peptide detection. GADA was positive in 43.7% of patients. Patients with detectable C-peptide levels had a lower mean age than the other patients (*p* = 0.001), but this link disappeared after the multivariate analysis. There was a correlation between overweight (BMI≥25 kg/m^2^) and undetectable C-peptide levels (*p* = 0.06).

Fasting glucose was not associated with C-peptide detection (*p* = 0.16). The patients with detectable C-peptide levels required lower insulin doses/kg than the other patients (0.61±0.34 vs. 0.85±0.28, *p*\<0.009), but had similar HbA1c levels (8.49±1.9 vs. 9.5±2.6, *p* = 0.182). These results were observed in the sample as a whole and separately in each group. C-peptide detection was also linked to a lower frequency of chronic complications (3.7% vs. 21.7%, *p* = 0.029) but not to retinopathy or nephropathy individually. In group 2, other autoimmune diseases (usually thyroid diseases) occurred more frequently in the patients with detectable C-peptide levels (*p* = 0.018). This association was not observed in group 1 (*p* = 0.53). After the logistic regression analysis, the link between the detectable C-peptide levels and the lower insulin doses (in use and with the Type-1 diabetes duration) remained significant.

DISCUSSION
==========

This study evaluated the frequency and clinical implications of C-peptide detection in Type-1 diabetes patients. This study population is particularly interesting because of the complex and mixed ethnic backgrounds of the patients. Most studies that have evaluated pancreatic function in Type-1 diabetes were performed in Caucasian and Asian patients. This study provides a unique opportunity to improve our knowledge of the progression of β-cell secretion in patients with Type-1 diabetes in our population because it is still unclear whether the results that were obtained in previous studies can be extrapolated to other ethnic populations, such as ours.

The tests were performed after the patients were stimulated with glucagon, which is a faster method for increasing β-cell secretion compared with the mixed meal test. However, nausea and flushing may occur more frequently as adverse events ([@b5-cln_68p123]). This study found that adverse events occurred in 35.2% of patients. These adverse events included mild and transient nausea (in most cases), which suggested that C-peptide measurement after glucagon infusion can be well tolerated. At the beginning of this study, both tests were considered equivalent in the literature ([@b7-cln_68p123]) and the mixed meal test was preferable ([@b13-cln_68p123]).

We have shown that a significant proportion of patients with Type-1 diabetes had detectable C-peptide levels, and these levels were higher than those observed in the Diabetes Control and Complications Trial Research Group DCCT ([@b8-cln_68p123],[@b10-cln_68p123]). We also compared the serum C-peptide levels between individuals with short and long disease durations (≤5 and \>5 years, respectively) of Type-1 diabetes. As expected, detectable C-peptide levels occurred more frequently in the individuals with shorter disease durations, which indicated that the progression of the β cell destruction occurred primarily during the first years of the disease ([@b8-cln_68p123]). However, a significant proportion of the patients with long-standing Type-1 diabetes had detectable levels of C-peptide. This finding was compatible with the anatomopathological data that described the presence of insulin cells in Type-1 diabetes patients with long disease durations ([@b5-cln_68p123]). In a group of patients with extremely favorable clinical outcomes and fewer diabetic complications, Keenan et al. have reported a surprisingly large number (18%) of Type-1 diabetes patients with disease durations \>50 years and detectable C-peptide levels ([@b17-cln_68p123]). Recently, using an ultrasensitive assay, Wang et al. have reported residual C-peptide levels in patients with long-standing Type-1 diabetes ([@b18-cln_68p123]). However, the potential clinical implications of sustained β-cell function have been reported only for those patients with C-peptide levels above the approximate threshold that was used in our study ([@b8-cln_68p123]).

One could question whether the patients with Type-1 diabetes and detectable C-peptide levels actually have Type-1 diabetes rather than other forms of diabetes. However, most patients needed insulin shortly after their diagnoses, were not overweight and lacked a significant family history of diabetes in more than one generation; these histories make other diagnoses, such as Type-2 diabetes and *Maturity Onset Diabetes of the Young* (MODY), unlikely. However, we cannot exclude the possibility that atypical forms of diabetes could be present in populations with mixed ethnic backgrounds, particularly those with GADA (-). Although the GADA prevalence was low in this study group ([@b19-cln_68p123]) it is likely that its positivity has decreased over the years ([@b20-cln_68p123],[@b21-cln_68p123]).

We found an association between autoimmune comorbidities and detectable C-peptide levels after stimulating patients with long disease durations, particularly in patients with thyroid diseases. Although the sample size was limited, this association has not been reported in other studies ([@b22-cln_68p123]). Vondra et al. reported the exact opposite association, with a lower frequency of autoimmune comorbidities in patients with Type-1 diabetes and detectable C-peptide levels ([@b23-cln_68p123]).

It is known that short- and long-term glycemic control may influence β-cell function in patients with Type-1 diabetes. However, previous data have indicated that residual pancreatic function may influence glycemic control ([@b8-cln_68p123],[@b24-cln_68p123],[@b25-cln_68p123]). In this study, we excluded patients with glycemia \<70 or \>200 mg/dl to minimize any possible interference. Although the patients with Type-1 diabetes and detectable C-peptide levels had similar glycemic control, these patients used lower daily insulin doses, which indicated that maintaining endogenous insulin secretion might reduce the insulin requirements of patients with Type-1 diabetes.

The association between chronic complications and residual C-peptide levels was also analyzed ([@b25-cln_68p123],[@b26-cln_68p123]). We found a link between C-peptide and chronic complications as a whole but not with retinopathy or nephropathy separately. It is possible that the sample size and the small number of individuals with chronic complications included in this study might have influenced our results.

To summarize, this study identified a significant number of individuals with Type-1 diabetes (of both short and long duration) with detectable C-peptide levels. It is possible that this residual β cell secretion is associated with a lower insulin requirement, a lower frequency of chronic complications and a higher frequency of other autoimmune diseases. However, prospective studies are still needed to resolve these questions.
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###### 

Clinical characteristics of patients grouped by disease durations.

                                           Disease duration                           
  ---------------------------------------- ------------------ ------------ ---------- ---------------
  **Sex Female n (%)**                     14(35.9)           34(68.8)     48(54.0)   **0.002**
  **  Male n (%)**                         25(64.1)           15(31.2)     40(46.0)   
  **Ethnicity White n (%)**                19(48.7)           32(64.6)     51(57.5)   0.13
  **  Non-white n (%)**                    20(51.3)           17(35.4)     37(42.5)   
  **Mean actual age (years)**              18.6±5.6           26.9±9.1     23.1±8.8   **\<0.001**
  **Mean diagnostic age (years)**          16.5±5.7           13.3±7.9     14.7±7.2   **0.004**
  **Mean disease duration (years)**        2.51±1.51          13.73±6.72   8.7± 7.6   **\<0.001**
  **DKA at diagnosis n (%)Yes**            8(20.5)            21(41.7)     29(33.0)   **0.022**
  **  No**                                 31(79.5)           27(56.3)     59(67.8)   
  **Mean BMI (kg/m^2^ ±SD)**               21.1±3.5           23.6±3.2     22.4±3.5   **\<0.001**
  **HbA1C (mean ±SD)**                     8.97±2.29          8.45±1.62    8.6±1.95   0.22
  **Mean insulin dose/kg**                 0.72±0.34          0.87±0.29    0.8±0.3    **0.023**
  **Detectable CP n (%)Fasting (CP1)**     16(41)             3(6.1)       19(21.6)   ***\<0.001***
  **  Stimulated (CP2)**                   23(63.9)           5(10.2)      28(31.8)   ***\<0.001***
  **Preserved CP n (%) Fasting (CP1)**     6(15.4)            1(2.0)       7(8)       ***0.029***
  **  Stimulated (CP2)**                   11(28.2)           2(4.1)       13(14.8)   ***0.009***
  **Other Auto-immune diseases n (%)\***   6 (15)             7(14.5)      13(14.7)   *0.95*
  **GADA**                                 24(62.5)           14(29.8)     38(43.7)   ***0.004***
  **Total number of patients**             **39**             **49**       **88**     

BMI -- Body mass index, HBA1c -- Glycohemoglobin, DKA- Diabetic ketoacidosis, CP -- C-peptide. \* Thyroid disease in 12 cases, Sjogren\'s syndrome and rheumatoid arthritis in one case each.
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